Takeda, Frazier create Phathom Pharmaceuticals to spur development of GI drug vonoprazan in $140M play
With fourteen gastroenterology assets in its pipeline, Takeda $TAK has its hands full. The company — newly merged with Shire — is thus farming out the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
